Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
172 hedge funds and large institutions have $1.9B invested in Acceleron Pharma in 2019 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 58 increasing their positions, 62 reducing their positions, and 8 closing their positions.
75% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 8
4% more funds holding
Funds holding: 166 → 172 (+6)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
4% less capital invested
Capital invested by funds: $1.97B → $1.9B (-$74.9M)
6% less repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 62
33% less call options, than puts
Call options by funds: $5.12M | Put options by funds: $7.66M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$20.5M |
| 2 |
Bank of New York Mellon
New York
|
+$11.3M |
| 3 |
BlackRock
New York
|
+$11M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$7.36M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$7.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$31.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$21.6M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$15.6M |
| 4 |
State Street
Boston,
Massachusetts
|
-$5.32M |
| 5 |
Two Sigma Investments
New York
|
-$5.32M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FRM
176
Fox Run Management
Greenwich,
Connecticut
| – | -$234K | -5,685 | Closed |
|
|
HF
177
HRT Financial
New York
| – | -$215K | -5,248 | Closed |
|
|
IWC
178
Integrated Wealth Concepts
Waltham,
Massachusetts
| – | -$205K | -5,000 | Closed |
|
|
WCA
179
Windsor Creek Advisors
Bethel,
Vermont
| – | -$205K | -5,000 | Closed |
|
180
Simplex Trading
Chicago,
Illinois
| – | -$209K | -4,826 | Closed |
|
XLRN Hedge Fund Activity: Q3 2019 in Review
172 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q3 2019, worth a combined $1.9B — down 3.8% from $1.97B a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new XLRN positions and 8 closed out — a net gain of 6 holders — while 58 added to existing stakes and 62 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $20.5M. The largest seller was Point72 Asset Management, cutting an estimated $31.5M.
- 172 institutional investors held Acceleron Pharma (XLRN) as of Q3 2019, up from 166 in Q2 2019.
- Funds reported $1.9B of Acceleron Pharma stock for Q3 2019, down 3.8% quarter-over-quarter.
- 14 funds opened new Acceleron Pharma positions in Q3 2019 and 8 closed out, a net change of +6 holders.
- The largest Acceleron Pharma buyer in Q3 2019 was Citadel Advisors, an estimated $20.5M added.
- The largest Acceleron Pharma seller in Q3 2019 was Point72 Asset Management, an estimated $31.5M sold.
Based on aggregated 13F filings for Q3 2019.